Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering

April 29, 2021

Cambridge, Mass., April 29, 2021 – Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered

April 24, 2024

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

WATERTOWN, Mass., April 24, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

April 23, 2024

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

WATERTOWN, Mass., April 23, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

April 5, 2024

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

WATERTOWN, Mass., April 05, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) Read More

Share this article: